Pyrosequencing/Mayo Deal Could Yield Thyroid Test ASR In Mid-2002
This article was originally published in The Gray Sheet
Pyrosequencing could make an analyte specific reagent (ASR) submission with FDA as early as mid-2002 for a test to detect an inherited form of thyroid cancer, under development with the Mayo Clinic
You may also be interested in...
ANALYTE SPECIFIC REAGENT LABELING CHANGES DUE BY NOV. 1998 UNDER FDA FINAL RULE; ASR MANUFACTURERS TO BE RESPONSIBLE FOR PREMARKET FILINGS, FDAers SAY
Analyte specific reagent manufacturers have until Nov. 23, 1998 to meet labeling and other requirements of the ASR final rule published by FDA Nov. 21. The one-year phase-in gives firms the opportunity to "deplete their current stock of labels," the agency explains.
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.